阿霉素（一种新型抗肿瘤抗生素）的临床评估
Clinical evaluation of adriamycin, a new antitumour antibiotic.
作者信息
Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F
出版信息
Br Med J. 1969 Aug 30;3(5669):503-6. doi: 10.1136/bmj.3.5669.503.
Abstract
Adriamycin, a new antitumour antibiotic of the anthracycline group with a structural formula very similar to daunorubicin, has proved to have potent tumour-growth-inhibiting properties, and to be particularly effective in childhood malignancies. Though adriamycin produces a higher percentage of side-effects than daunorubicin-namely, stomatitis and alopecia-a lower dosage may be used for therapy.
摘要
阿霉素是一种蒽环类新型抗肿瘤抗生素，其结构式与柔红霉素非常相似，已证明具有强大的肿瘤生长抑制特性，尤其对儿童恶性肿瘤有效。尽管阿霉素产生副作用的比例比柔红霉素高，即口腔炎和脱发，但治疗时可以使用较低剂量。
相似文献
1
Clinical evaluation of adriamycin, a new antitumour antibiotic.
Br Med J. 1969 Aug 30;3(5669):503-6. doi: 10.1136/bmj.3.5669.503.
2
[A new antibiotic with antineoplastic activity: rubidomycin (13.057 R.P.)].
Arzneimittelforschung. 1967 Aug;17(8):955-9.
3
Phase I and preliminary phase II evaluation of adriamycin (NSC 123127).
Cancer Res. 1970 Oct;30(10):2572-82.
4
Adriamycin in the treatment of childhood acute leukemia. A Southwest Oncology Group study.
Cancer. 1975 Oct;36(4):1223-6. doi: 10.1002/1097-0142(197510)36:4<1223::aid-cncr2820360407>3.0.co;2-7.
5
Adriamycin in the treatment of acute leukaemia.
Br Med J. 1972 Feb 19;1(5798):482-3. doi: 10.1136/bmj.1.5798.482.
6
Anthracyclines in the treatment of cancer. An overview.
Drugs. 1997;54 Suppl 4:1-7. doi: 10.2165/00003495-199700544-00003.
7
Daunorubicin (NSC 82151) in the treatment of advanced childhood lymphoblastic leukemia.
Cancer Res. 1971 Feb;31(2):84-90.
8
[Rubidomycine. A new antineoplastic antibiotic].
Munch Med Wochenschr. 1968 Jun 21;110(25):1539-41.
9
Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
Semin Oncol. 1993 Dec;20(6 Suppl 8):47-52.
10
Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease.
Cancer. 1971 Oct;28(4):837-43. doi: 10.1002/1097-0142(1971)28:4<837::aid-cncr2820280406>3.0.co;2-4.
引用本文的文献
1
Influence of Polymorphisms in Pharmacokinetics-Related Genes on the Areas Under the Plasma Concentration-Time Curves of Doxorubicin and Doxorubicinol in Patients with Diffuse Large B-Cell Lymphoma Receiving CHOP Therapy.
Eur J Drug Metab Pharmacokinet. 2025 May;50(3):219-227. doi: 10.1007/s13318-025-00940-9. Epub 2025 Apr 4.
2
Synergistic effects and competitive relationships between DOC and DOX as acting on DNA molecules: Studied with confocal Raman spectroscopy and molecular docking technology.
Heliyon. 2024 Apr 23;10(9):e30233. doi: 10.1016/j.heliyon.2024.e30233. eCollection 2024 May 15.
3
Doxorubicin alters G-protein coupled receptor-mediated vasocontraction in rat coronary arteries.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Aug;397(8):5831-5845. doi: 10.1007/s00210-024-02988-x. Epub 2024 Feb 8.
4
The role of hesperidin as a cardioprotective strategy against doxorubicin-induced cardiotoxicity: The antioxidant, anti-inflammatory, antiapoptotic, and cytoprotective potentials.
Open Vet J. 2023 Dec;13(12):1718-1728. doi: 10.5455/OVJ.2023.v13.i12.20. Epub 2023 Dec 31.
5
Electrochemically Enabled Total Syntheses of Natural Products.
ChemElectroChem. 2023 Jun 1;10(11). doi: 10.1002/celc.202300140. Epub 2023 May 2.
6
The Metabolic Fingerprint of Doxorubicin-Induced Cardiotoxicity in Male CD-1 Mice Fades Away with Time While Autophagy Increases.
Pharmaceuticals (Basel). 2023 Nov 15;16(11):1613. doi: 10.3390/ph16111613.
7
to clinical translation of combinatorial effects of doxorubicin and dexrazoxane in breast cancer: a mechanism-based pharmacokinetic/pharmacodynamic modeling approach.
Front Pharmacol. 2023 Oct 19;14:1239141. doi: 10.3389/fphar.2023.1239141. eCollection 2023.
8
Hyperhomocysteinaemia Promotes Doxorubicin-Induced Cardiotoxicity in Mice.
Pharmaceuticals (Basel). 2023 Aug 28;16(9):1212. doi: 10.3390/ph16091212.
9
Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer.
J Transl Med. 2023 Sep 19;21(1):635. doi: 10.1186/s12967-023-04498-5.
10
Novel molecular mechanisms of doxorubicin cardiotoxicity: latest leading-edge advances and clinical implications.
Mol Cell Biochem. 2024 May;479(5):1121-1132. doi: 10.1007/s11010-023-04783-3. Epub 2023 Jun 13.
本文引用的文献
1
Meaningful clinical classification of therapeutic responses to anticancer drugs.
Clin Pharmacol Ther. 1961 Nov-Dec;2:709-12. doi: 10.1002/cpt196126709.
2
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
Cancer Chemother Rep. 1969 Feb;53(1):33-7.
3
Rubidomycin in acute leukaemia in adults.
Br Med J. 1968 Jul 27;3(5612):227-9. doi: 10.1136/bmj.3.5612.227.
4
[Therapy with daunomycin in chronic lymphoproliferative diseases].
Tumori. 1968 Nov-Dec;54(6):465-81. doi: 10.1177/030089166805400605.
5
[Cardiac complications observed during treatment with rubidomycin].
Pathol Biol. 1967 Oct;15(19):949-53.
6
Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia.
Cancer. 1967 Mar;20(3):333-53. doi: 10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k.
7
Cardiac toxicity of daunorubicin.
Lancet. 1969 Apr 19;1(7599):837-8.
8
Cardiac toxicity of daunorubicin.
Lancet. 1969 Apr 19;1(7599):837.
9
Daunorubicin in acute myelocytic leukaemia.
Lancet. 1969 Mar 1;1(7592):469-70. doi: 10.1016/s0140-6736(69)91516-5.
10
Daunorubicin in the treatment of acute myelocytic leukaemia.
Lancet. 1969 Feb 15;1(7590):330-3. doi: 10.1016/s0140-6736(69)91296-3.
Zotero 插件